Cryoballoon ablation for the treatment of atrial fibrillation in Kazakhstan: One year outcome from the Cryo Global Registry.

Q3 Medicine

Indian Pacing and Electrophysiology Journal Pub Date : 2025-06-20 DOI:10.1016/j.ipej.2025.06.008

Ayan Abdrakhmanov, Omirbek Nuralinov, Gulzhaina Rashbayeva, Azat Tursunbekov, Serik Bagibayev, Abay Bakytzhanuly, Zhandos Yessilbayev, Assel Chinybayeva, Zhanar Abdrakhmanova, Alessandro Salustri, Zhanasyl Suleymen, Rano Kirkimbayeva

{"title":"Cryoballoon ablation for the treatment of atrial fibrillation in Kazakhstan: One year outcome from the Cryo Global Registry.","authors":"Ayan Abdrakhmanov, Omirbek Nuralinov, Gulzhaina Rashbayeva, Azat Tursunbekov, Serik Bagibayev, Abay Bakytzhanuly, Zhandos Yessilbayev, Assel Chinybayeva, Zhanar Abdrakhmanova, Alessandro Salustri, Zhanasyl Suleymen, Rano Kirkimbayeva","doi":"10.1016/j.ipej.2025.06.008","DOIUrl":null,"url":null,"abstract":"Introduction: Atrial fibrillation (AF) is a prevalent and potentially serious cardiac rhythm disorder. Cryoballoon ablation using the Arctic Front catheter offers a modern treatment approach. This subanalysis evaluates the safety, efficacy, and impact on quality of life for patients undergoing t this procedure in Kazakhstan. The Cryo AF Global Registry (NCT02752737) is an ongoing prospective, multi-center observational post-market registry collecting global data on CBA procedures conducted with the Arctic Front™ Family of Cardiac Cryoablation Catheters.Methods: The study included patients aged 18 and older with paroxysmal, persistent, and long-standing persistent AF. Key safety endpoints included serious adverse events related to the device or procedure. Efficacy was measured by the absence of AF, atrial flutter (AFL), and/or atrial tachycardia (AT) after a 90-day period of discontinuing antiarrhythmic medications.Results: No injuries to the phrenic nerve or serious complications were reported. Three serious adverse events occurred, but these were not related to the procedure. At 12 months, the Kaplan-Meier analysis showed a 92.9 % rate of freedom from AF or other atrial arrhythmias after the 90-day blanking period. Two repeat ablations (2.9 %) were needed for AF.Conclusion: This analysis supports the conclusion that cryoballoon ablation is both safe and effective for treating AF in Kazakhstan, resulting in significant improvements in patients' quality of life.Registration number: NCT02752737.","PeriodicalId":35900,"journal":{"name":"Indian Pacing and Electrophysiology Journal","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Pacing and Electrophysiology Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.ipej.2025.06.008","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Atrial fibrillation (AF) is a prevalent and potentially serious cardiac rhythm disorder. Cryoballoon ablation using the Arctic Front catheter offers a modern treatment approach. This subanalysis evaluates the safety, efficacy, and impact on quality of life for patients undergoing t this procedure in Kazakhstan. The Cryo AF Global Registry (NCT02752737) is an ongoing prospective, multi-center observational post-market registry collecting global data on CBA procedures conducted with the Arctic Front™ Family of Cardiac Cryoablation Catheters.

Methods: The study included patients aged 18 and older with paroxysmal, persistent, and long-standing persistent AF. Key safety endpoints included serious adverse events related to the device or procedure. Efficacy was measured by the absence of AF, atrial flutter (AFL), and/or atrial tachycardia (AT) after a 90-day period of discontinuing antiarrhythmic medications.

Results: No injuries to the phrenic nerve or serious complications were reported. Three serious adverse events occurred, but these were not related to the procedure. At 12 months, the Kaplan-Meier analysis showed a 92.9 % rate of freedom from AF or other atrial arrhythmias after the 90-day blanking period. Two repeat ablations (2.9 %) were needed for AF.

Conclusion: This analysis supports the conclusion that cryoballoon ablation is both safe and effective for treating AF in Kazakhstan, resulting in significant improvements in patients' quality of life.

Registration number: NCT02752737.

查看原文本刊更多论文

冷冻球囊消融在哈萨克斯坦治疗房颤：来自冷冻全球注册的一年结果。

心房颤动（AF）是一种普遍且潜在严重的心律失常。使用Arctic Front导管的低温球囊消融提供了一种现代治疗方法。该亚分析评估了哈萨克斯坦接受该手术的患者的安全性、有效性和对生活质量的影响。Cryo AF全球注册（NCT02752737）是一项正在进行的前瞻性、多中心观察性上市后注册，收集使用Arctic Front™系列心脏冷冻消融导管进行CBA手术的全球数据。方法：研究纳入18岁及以上阵发性、持续性和长期持续性房颤患者。主要安全终点包括与设备或手术相关的严重不良事件。通过停用抗心律失常药物90天后房颤、心房扑动（AFL）和/或房性心动过速（AT）的消失来衡量疗效。结果：无膈神经损伤及严重并发症。发生了三个严重的不良事件，但这些与手术无关。在12个月时，Kaplan-Meier分析显示，在90天的空白期后，房颤或其他心房心律失常的自由率为92.9%。AF需要两次重复消融（2.9%）。结论：本分析支持冷冻球囊消融在哈萨克斯坦治疗AF安全有效，显著改善患者生活质量的结论。注册号：NCT02752737。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Indian Pacing and Electrophysiology Journal Medicine-Cardiology and Cardiovascular Medicine

CiteScore

2.20

自引率

0.00%

发文量

审稿时长

61 days

期刊介绍： Indian Pacing and Electrophysiology Journal is a peer reviewed online journal devoted to cardiac pacing and electrophysiology. Editorial Advisory Board includes eminent personalities in the field of cardiac pacing and electrophysiology from Asia, Australia, Europe and North America.